The Hindu Business Line : Hindustan Bio gets nod for importing anaemia drug

HINDUSTAN Bio Sciences Ltd (HBSL) has announced that it has obtained approvals from the Genetic Engineering Approval Committee (GEAC) of the Government of India for importing and marketing recombinant human erythropoietin - bioengineered product.

In a press release, the company said erythropoietin manufactured in China by Shandong Kexing Bio Products Company Ltd and HBSL would be marketed in India soon. Erythropoietin is used in treatment of all kinds of anaemia resulting from chronic renal failure, cancer and AIDS. HBSL proposes to launch the recombinant human erythropoietin in the Indian market under the brand `Eposino' targeting mainly the middle and lower income group patientsunlike similar drugs in the market, such as `Eprex' of Johnson & Johnson, `Hemax' of Hindustan Anti Biotech and `Zyrop' of Zydus Biogen, which, HBSL says, were expensive. When contacted, the HBSL General Manager, Mr K. Ramachandra Raju, told Business Line that the company obtained GEAC approvals in March. Stating that the company is yet to obtain approval from the DCGI, Mr Raju said it was also required to conduct small-scale safety and efficacy studies on patients for launching the product.

More Stories on : Announcements | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
VSP to invest Rs 1,000 cr in iron ore, coal mining

Allied Domecq drops IMFL plans; to focus on international portfolio

Honda cars to cost more

Hindustan Bio gets nod for importing anaemia drug

Karvy to be HLL's registrar, transfer agent

MECON made consultant for Rashtriya Ispat project

SPS Sponge plans Rs 380-cr plant in Orissa

`Export and retail plans in the pipeline'

Keltec turns around

Tata Tea to boost global presence — Focus to remain on branded business

Maruti's used car, insurance businesses see robust growth

V.K. Magapu joins L&T board as whole-time director